Bismuth-Based Quad Tx Doesn't Top Levofloxacin Triple Tx

This article originally appeared here.
Share this content:
Bismuth-Based Quad Tx Doesn't Top Levofloxacin Triple Tx
Bismuth-Based Quad Tx Doesn't Top Levofloxacin Triple Tx

FRIDAY, July 14, 2017 (HealthDay News) -- For patients with Helicobacter pylori infection, the addition of bismuth subcitrate to levofloxacin-based triple therapy is not associated with increased effectiveness, although there are no more side effects, according to a study published online June 23 in the Journal of Digestive Diseases.

Tzung-Shiun Wu, from the Kaohsiung Medical University Hospital in Taiwan, and colleagues conducted a prospective study involving 67 patients infected with H. pylori. Patients were randomized to receive levofloxacin plus bismuth-based quadruple therapy (RBAL) for 10 days (33 patients) or levofloxacin-based triple therapy (RAL) for 10 days (34 patients). The response was assessed using endoscopy performed four to eight weeks after eradication.

The researchers found that both groups showed similar eradication rates (84.8 and 67.6 percent for RBAL and RAL, respectively; P = 0.373) in intention-to-treat analysis. There was no significant difference in compliance (P = 1.031); adverse events were also similar between the groups. Most cases of eradication failure were levofloxacin resistant.

"Levofloxacin-resistant rate may be a more important role when choosing second-line therapy," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Ground Beef Recalled After E. Coli Outbreak

Ground Beef Recalled After <i>E. Coli</i> Outbreak

Beef was produced and packaged at Cargill Meat Solutions in Fort Morgan, Colo.

Prevalence of Alzheimer's, Related Dementia Set to Double

Prevalence of Alzheimer's, Related Dementia Set to Double

Alzheimer's disease and related dementias burden is expected to increase to 3.3 percent in 2060

Long-Term Outcomes of Breast Implants Explored

Long-Term Outcomes of Breast Implants Explored

Higher rates of Sjogren syndrome, scleroderma, RA, stillbirth, melanoma for silicone implants

is free, fast, and customized just for you!




Already a member?

Sign In Now »